CURRENT
ISSUE
1604

Artesunate for injection (Amivas LLC), a semi-synthetic artemisinin derivative, is now approved by the FDA for initial (induction) treatment of severe malaria in children and adults. It has been available from the CDC on a compassionate use basis since 2007.1 Artemether/lumefantrine (Coartem), another artemisinin-based drug, was approved earlier for oral treatment of uncomplicated Plasmodium falciparum malaria.2 IV artesunate is now the only FDA-approved injectable antimalarial drug available in the US; IV quinidine has been discontinued.

SEVERE MALARIA — Complications of severe malaria, which...  Continue reading

More from Issue 1604
Previous Issue: 1603      July 27, 2020
Coming Soon
Cenobamate (Xcopri) for Epilepsy
Ozanimod (Zeposia) for Multiple Sclerosis
Drugs for COPD
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
Advance Release
ADVANCE
RELEASE

The FDA has approved Phexxi (Evofem), a nonhormonal prescription-only vaginal gel containing lactic acid, citric acid, and potassium bitartrate, for prevention of pregnancy. The gel is intended for on-demand contraception; it is not effective when used after intercourse. It was previously approved for use as a vaginal lubricant (Amphora), but was never marketed.Continue reading

Advance Release
ADVANCE
RELEASE

A transdermal formulation of the second-generation (atypical) antipsychotic asenapine (Secuado – Noven) has been approved by the FDA for once-daily treatment of schizophrenia in adults. Asenapine is the first antipsychotic to become available in a transdermal formulation in the US. A twice-daily sublingual tablet formulation of asenapine (Saphris) has been available since ... Continue reading

 Tweets